In this case study, Patrick McGill, MD, executive vice president and chief transformation officer with Community Health Network, introduces the Galleri test and its innovative value.
In the United States, cancer is the second leading cause of death. And yet, there are not recommended screenings for approximately 70 percent of cancers today.
But now that could change for the better.
Thanks to the support of the Community Health Network Foundation, the Galleri® multi-cancer early detection test became available to primary care doctors within the healthcare system, which has more than 200 sites of care and affiliates in central Indiana.
The blood test, which is the first of its kind, uses advanced genomics and machine learning to analyze DNA in the blood for a cancer signal. When the test detects a cancer signal, it's able to predict the origin of the cancer, which helps guide further diagnostic testing.
In this case study, Patrick McGill, MD, executive vice president and chief transformation officer with Community Health Network, explains why the Galleri test, when used in conjunction with guideline-based cancer screenings, offers doctors and patients new hope in cancer diagnosis and treatment.
Offered Free by: Healthcare Dive's studioID & Grail
See All Resources from: Healthcare Dive's studioID & Grail